Mirum says Phase 3 AZURE-1 trial meets primary endpoint for brelovitug in chronic hepatitis delta virus

• Mirum reported Phase 3 AZURE-1 met its primary endpoint for brelovitug in chronic hepatitis delta at Week 24.
• Results showed the drug improved viral control and liver inflammation versus delayed treatment, supporting its potential as a single-agent therapy.
• Longer-term Phase 2b data through Week 48 showed responses continued to strengthen with extended dosing.
• Full Phase 3 results will be presented at a future medical congress; AZURE-4 topline data are expected in Q4 2026.
• Planning a U.S. BLA submission in H1 2027; targeting a potential U.S. launch in Q4 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609280800BIZWIRE_USPR_____20260928_BW804552) on September 28, 2026, and is solely responsible for the information contained therein.